329 related articles for article (PubMed ID: 30858551)
1. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
Sun Y; Ding N; Song Y; Yang Z; Liu W; Zhu J; Rao Y
Leukemia; 2019 Aug; 33(8):2105-2110. PubMed ID: 30858551
[No Abstract] [Full Text] [Related]
2. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
4. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
Lenz G
J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
[No Abstract] [Full Text] [Related]
5. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Hanna KS; Campbell M; Husak A; Sturm S
J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
[TBL] [Abstract][Full Text] [Related]
6. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
7. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.
Sun Y; Zhao X; Ding N; Gao H; Wu Y; Yang Y; Zhao M; Hwang J; Song Y; Liu W; Rao Y
Cell Res; 2018 Jul; 28(7):779-781. PubMed ID: 29875397
[No Abstract] [Full Text] [Related]
8. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Buhimschi AD; Armstrong HA; Toure M; Jaime-Figueroa S; Chen TL; Lehman AM; Woyach JA; Johnson AJ; Byrd JC; Crews CM
Biochemistry; 2018 Jul; 57(26):3564-3575. PubMed ID: 29851337
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
10. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
Ahmed M; Lorence E; Wang J; Jung D; Zhang L; Nomie K; Wang M
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723172
[TBL] [Abstract][Full Text] [Related]
11. [Ibrutinib: A new drug of B-cell malignancies].
Thieblemont C
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Brown JR
Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib for the treatment of mantle cell lymphoma.
Shah N; Hutchinson C; Rule S
Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
Zhang L; Newberry KJ; Wang M
Expert Rev Clin Immunol; 2013 Jun; 9(6):495-7. PubMed ID: 23730878
[No Abstract] [Full Text] [Related]
15. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
18. Targets for Ibrutinib Beyond B Cell Malignancies.
Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Rule SA; Cartron G; Fegan C; Morschhauser F; Han L; Mitra S; Salles G; Dyer MJS
Leukemia; 2020 May; 34(5):1458-1461. PubMed ID: 31827243
[No Abstract] [Full Text] [Related]
20. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
